Optimized 2-methoxyestradiol invasomes fortified with apamin: a promising approach for suppression of A549 lung cancer cells

Zuhier A. Awan, Shareefa A. AlGhamdi, Nabil A. Alhakamy, Solomon Z. Okbazghi, Mohamed A. Alfaleh, Shaimaa M. Badr-Eldin, Hibah M. Aldawsari, Mohammed A. S. Abourehabi, Hani Z. Asfour, Shadi A. Zakaik, Mohammad W. Alrabia, Aya A. Negm, Mohamed A. El-Moselhy, Sara S. Sharkawi and Waleed Y. Rizg

ABSTRACT
Certain anticancer agents selectively target the nucleus of cancer cells. One such drug is 2-methoxyestradiol (2ME), which is used for treating lung cancer. To improve the therapeutic effectiveness of these agents, many new methods have been devised. 2ME was entrapped into the core of hydrophobic invasomes (INVA) covered with Phospholipon 90G and apamin (APA). The Box–Behnken statistical design was implemented to enhance the composition. Using Design-Expert software (Stat-Ease Inc., Minneapolis, MN), the INVA component quantities were optimized to obtain spherical particles with the smallest size, that is, a diameter of 167.8 nm. 2ME-INVA-APA significantly inhibited A549 cells and exhibited IC_{50} of 1.15 ± 0.04 μg/mL, which is lower than raw 2ME (IC_{50} 5.6 ± 0.2 μg/mL). Post 2ME-INVA-APA administration, a significant rise in cell death and necrosis was seen among the A549 cells compared to those treated with plain formula or 2ME alone. This effect was indicated by increased Bax expression and reduced Bcl-2 expression, as well as mitochondrial membrane potential loss. Moreover, the cell cycle analysis showed that 2ME-INVA-APA arrests the G2-M phase of the A549 cells. Additionally, it was observed that the micellar formulation of the drug increased the cell count in pre-G1, thereby exhibiting phenomenal apoptotic potential. Furthermore, it up-regulates caspase-9 and p53 and downregulates TNF-α and NF-κB. Collectively, these findings showed that our optimized 2ME-INVA-APA could easily seep through the cell membrane and induce apoptosis in relatively low doses.

1. Introduction
One of the most common and rapidly increasing types of cancer is lung cancer (LC), of which non-small cell LC (NSCLC; 85%) is more common than small cell LC (SCLC; 15%) (Teramoto et al., 1999; Lemjabbar-Alaoui et al., 2015; Wei et al., 2020). One of the major causative factors of LC is smoking, while other common factors include chronic obstructive pulmonary disease (COPD), air pollution, and occupational hazards such as inhalation of toxic gases. Notably, LC is also caused, albeit rarely, due to dietary and genetic factors (Amirshahrokhi & Bohlooli, 2013). Unfortunately, LC is associated with a staggering mortality rate. Treatment plan includes surgery, adjuvant therapy, chemotherapy, and radiotherapy (Lemjabbar-Alaoui et al., 2015; Herbst et al., 2018).

2-Methoxyestradiol (2ME, Figure 1A) is a naturally occurring metabolite of estrogen, with anti-proliferative and anti-angiogenic properties, which can help arrest the growth and potentially destroy cancer cells. 2ME shows zero estrogenic property stems from its ability to initiate apoptosis by inhibiting hypoxia-inducible factor 1 and activating p53 (Pillai et al., 2017). Certain studies have observed that 2ME binds to tubulin, thereby stopping mitosis by forming microtubule (Lakhani et al., 2003). A report deemed 2ME effective in fighting prostate cancer, although the plasma concentration of 2ME does not sustain for long (Sweeney et al., 2005).
It was noted that a significantly high dose was required in human beings when administered orally; however, nano-2ME formulation shows enhanced pharmacokinetic properties in animal test subjects (Wang et al., 2011; Alhakamy et al., 2021).

Invasomes (INVA) are innovative elastic vesicles made of several chemicals, including terpene(s), ethanol, and phosphatidylcholine (Ahmed & Badr-Eldin, 2019), which enhance the absorption of water soluble and lipid soluble drugs (Alhakamy et al., 2021). This enhancement can likely be attributed to terpenes, which break down the tightly packed lipids in epidermal (Ahmed & Badr-Eldin, 2019) and engage with intracellular proteins (Attalla et al., 1996). Similarly, ethanol helps the drugs seep through the stratum corneum. Moreover, it exhibits anti-angiogenic action through electrostatic repulsion by maintaining a negative surface charge (Ahmed & Badr-Eldin, 2019). INVA have shown promising activity against MCF-7 breast cancer cell line (Vidya & Lakshmi, 2019).

Apamin (APA, Figure 1(B)), a peptide present in bee venom (apitoxin), has been employed in the delivery of specific drugs. APA has a wide range of pharmacological activities that might be modified for therapeutic purposes (Gu et al., 2020; Alhakamy et al., 2021). Furthermore, the cytotoxic action of bee venom components has been documented.

Accordingly, the aim of this study was to formulate and optimize 2ME INVA fortified by APA that possess the least possible vesicle size. The Box–Behnken design was implemented to achieve this target. The optimized formulation was then tested for in vitro anticancer activity against LC cells.

2. Materials

For this study, 2ME was obtained from Jinlan-Pharm-Drugs Technology Co., Ltd. (Hangzhou, China); terpene (α-limonene and β-citronellol), APA, methanol, and acetonitrile from Sigma-Aldrich (St. Louis, MO); Phospholipon® 90G (purified soybean lecithin with a phosphatidylcholine content of at least 90%) from Lipoid GmbH (Ludwigshafen, Germany).

3. Methods

3.1. Preparation of 2ME-INVA-APA

The preparation method built by Ahmed & Badr-Eldin (2019) was adopted to formulate 2ME-INVA-APA, but with modifications. Phospholipon® 90G and 2ME (100 mg) were dissolved in a 1:2, v/v ratio of methanol/chloroform combination. The prepared solution was then rotated in a rotary evaporator (model R-200, Buchi, Essen, Germany) in order to eliminate the organic solvent. Then, a thin lipid film was formed and stored in a cabinet with vacuum system (model 5831, Thermo Fisher Scientific, Waltham, MA) overnight to remove any solvent traces. After that, terpene was applied to the performed lipid films, and then a combination of phosphate buffer saline/ethanol with a ratio of 7:3 (pH 7.4) was added. To produce a final volume of 10 mL, then the combination was rotated for 1 h at 25°C. The resulting vesicles were kept at 25°C for a period of time (1 h) in order to let them swell. To reach the appropriate particle size, the vesicles were ultrasonicated for 8 min per cycle for two cycles in an ice bath using a Sonics Viera Cell microtip with an amplitude of 40%, 750 W, 20 kHz (Sonics & Materials Inc., Newtown, CT). Then, APA (1 mg) was applied to the vesicles, and then they were stirred for 30 min at room temperature. The obtained vesicles were stored under nitrogen.

3.2. Experimental design

A design software, which is Box–Behnken design with a three-factor, was used in order to adjust 2ME-INVA-APA.
utilizing Design-Expert version software (Version 12, Stat-Ease Inc., Minneapolis, MN). Phospholipid % (X_1), ethanol % (X_2), and terpene % (X_3) were utilized as independent variables. Invasomes size was studied as a response (Y). Table 1 lists each factor the coded levels, which designated as (-1, 0, +1), as well as their definite values. In this experiment, 15 runs were performed. Table 2 summarizes the runs and the results. For the purpose of selecting the best fitting model for the measured response, statistical parameters such as predicted and adjusted determination coefficients, as well as an adequate precision ratio, were computed and used. The best-fitting model was represented by the corresponding polynomial equation. The measured response was statistically analyzed using analysis of variance (ANOVA) to estimate the significance of the studied variables at 95% level of significance. Perturbation and 3D plots were produced to present the main effects of the variables and the interaction between them. To reduce vesicle size, the analyzed variables were optimized using a numerical technique based on the desirability approach.

### 3.3. Vesicle size measurement

The vesicular size and polydispersity index (PDI) of 2ME-INVA-APA (Zetasizer Nano ZSP, Malvern Panalytical, Malvern, UK) were measured using the dynamic light scattering technique and calculated as the mean of five determinations. The laser wavelength was 633 nm, scattering angle of 173, temperature of 25°C, medium viscosity of 0.8872 cP, and medium refractive index of 1.33.

### 3.4. Calculating IC\textsubscript{50} through MTT assay

The MTT viability assay [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] was conducted in order to obtain the IC\textsubscript{50} values of untreated A549 cells (control) after treatment with blank-INVA (INVA-APA), 2ME, or 2ME-INVA-APA for 48 h (Caruso et al., 2017). Then, in a 96-well plate, A549 cells (1 × 10\textsuperscript{5} cells) were seeded and incubated overnight. Afterwards, these were treated with the plain (INVA-APA), 2ME, or 2ME-INVA-APA at (0.39 μM, 1.56 μM, 6.26 μM, 25 μM, and 100 μM). After 48 hours, the utilized medium was changed to solution (MTT) with the concentration of 2 mg/mL and then prepared plates were placed in an incubator for 4 h at 37°C. After that, 200 μL of 100% DMSO was added in order to eliminate the formazan, and then the plates were incubated in a 5% CO\textsubscript{2} at 37°C for 5 min. Then, a microplate reader (Spark\textsuperscript{\textregistered} multimode, Tecan Group Ltd., Maennedorf, Switzerland) identified an absorbance at 569 nm in each well. The results were presented in terms of percent cell viability relative to the control. Following the plotting of dose response curves, GraphPad Prism (GraphPad, Inc., La Jolla, CA), was used to define the IC\textsubscript{50} value for each of the experimental conditions.

### 3.5. Cell cycle analysis

The cell cycle phases of A549 cells were studied using flow cytometry (FACScalibur, BD Bioscience, Franklin Lakes, NJ) (Alfaifi et al., 2020). Six-well plates were utilized to seed the cells in a density of 3 × 10\textsuperscript{5} cells/well. These were divided into two: untreated (control) or treated group (treated with plain (INVA-APA), 2ME, or 2ME-INVA-APA) left for 24 hours. Next, the cells were washed; 70% cold ethanol was used to fix the cells, and RNase staining buffer and propidium iodide (PI) were used to stain them. Flow cytometry resulted in 10,000 gated events. MultiCycle AV was used to analyze the data (Phoenix Flow Systems, San Diego, CA).

### 3.6. Annexin V-FITC apoptosis assay

In this part, an Annexin V-FITC Apoptosis Detection kit (BioVision, Cambridge BioSciences, Cambridge, UK) was utilized in order to observe the apoptotic effects of INVA-APA, 2ME, and 2ME-INVA-APA on A549 cells. Six-well plates were used to seed the cells at a density of 1 × 10\textsuperscript{6} cells/well. These were split into two: untreated (control) and treated group (treated with plain (INVA-APA), 2ME, or 2ME-INVA-APA) left for 24 hours. Following this, the cells were first centrifuged to separate them. Then, PBS buffer was used to wash them. After washing, 500 μL of 1× binding buffer was applied to the cells. Then, they were stained with PI and annexin V-FITC for flow cytometry. For each treatment, flow cytometry yielded a minimum of 20,000 events. The data were analyzed using MultiCycle AV.

### Table 1. Independent variables and responses utilized for the formulation of the 2ME-INVA-APA in the Box–Behnken design software.

| Independent variable | Levels | Desirability constraints |
|----------------------|--------|-------------------------|
| X\textsubscript{1}: phospholipid % | 5, 10, 15 | |
| X\textsubscript{2}: ethanol % | 1, 2, 3 | |
| X\textsubscript{3}: terpene % | 1, 1.5, 2 | |
| Y: vesicle size (nm) | | Minimize |

2ME: 2-methoxyestradiol; INVA: invasomes; APA: apamin.

### Table 2. Experimental runs of the prepared 2ME-INVA-APA corresponding to design Box–Behnken software and their measured vesicle size.

| Run # | Phospholipid % | Ethanol % | Terpene % | Vesicle size (nm) |
|-------|----------------|-----------|-----------|------------------|
| 1     | 15             | 2         | 2         | 368.7            |
| 2     | 10             | 1.5       | 2         | 279.4            |
| 3     | 10             | 1.5       | 2         | 268.3            |
| 4     | 5              | 1.5       | 1.5       | 229.3            |
| 5     | 15             | 1.5       | 1         | 418.3            |
| 6     | 15             | 1.5       | 1.5       | 296.5            |
| 7     | 5              | 2         | 1         | 191.7            |
| 8     | 5              | 1.5       | 1.5       | 173.2            |
| 9     | 10             | 2         | 2         | 251.8            |
| 10    | 10             | 1         | 1         | 289.7            |
| 11    | 10             | 3         | 1         | 219.9            |
| 12    | 15             | 2         | 1         | 311.4            |
| 13    | 10             | 1         | 2         | 328.1            |
| 14    | 5              | 2         | 2         | 213.1            |
| 15    | 10             | 2         | 1.5       | 272.1            |

2ME: 2-methoxyestradiol; INVA: invasomes; APA: apamin.
3.7. Real-time polymerase chain reaction (RT-qPCR)

3.7.1. RNA extraction
A Qiagen RNeasy mini kit (Qiagen, Manchester, UK) RNA was utilized to extract the RNA from the selected cells (A594 cells). The RNA’s purity and concentration were verified using a Nanodrop Spectrophotometer (ND-2000C, Thermo Fisher Scientific, Waltham, MA). All RNA samples had an $A_{260\text{ nm}}/A_{230\text{ nm}}$ ratio of not less than 1.8 and an $A_{260\text{ nm}}/A_{280\text{ nm}}$ ratio of not less than 1.9.

3.7.2. cDNA synthesis and PCR amplification
A Green kit (iScript™ One-Step RT-PCR Kit With SYBR® (BioRad, Hercules, CA)) was utilized (cDNA) in order to normalize RNA between tubes and reverse transcribe it to complementary DNA. The expression patterns of p53, Bax, Bcl-2, casp3, TNF- and NFB, and $\alpha$-actin were studied using 10 ng of RNA template in a 50-μL reaction mixture of iScript one-step RT-PCR kit with SYBR® Green mix and a 7500 Fast real-time PCR machine (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA).

Figure 2. Diagnostic plots for particle size of 2ME-INVA-APA. (A) Power transforms Box–Cox plot for, (B) outwardly predicted vs. studentized residuals values, (C) outwardly run number vs. studentized residuals, and (D) actual values plot vs. predicted. 2ME: 2-methoxyestradiol; INVA: invasomes; APA: apamin.

Table 3. Measured vesicle size statistical analysis output of 2ME-INVA-APA according to two factor interaction model.

| $R^2$ | Adjusted $R^2$ | Predicted $R^2$ | Adequate precision | Sequential p value | Lack of fit p value |
|-------|----------------|----------------|--------------------|--------------------|-------------------|
| 0.9884| 0.9943         | 0.9872         | 21.1491            | 0.0017             | 0.7169            |

$p$ Value of significant terms $\chi_1$, $\chi_2$, $\chi_0$, $\chi_1\chi_2$, $\chi_1\chi_0$, $\chi_2\chi_0$, all < .0001.

2ME: 2-methoxyestradiol; INVA: invasomes; APA: apamin.
3.7.3. Mitochondrial membrane potential (MMP)
The MMP levels in A549 cells seeded in 96-well plates (1 x 10^5 cells/well) and treated to INVA-APA, 2ME, or 2ME-INVA-APA for 24 hours were monitored using an assay kit (MitoProbe TMRM) (Alhakamy et al., 2020). INVA-APA, 2ME, or 2ME-INVA-APA were used at IC50 concentrations.

3.8. Statistical analysis
GraphPad Prism (GraphPad, Inc., La Jolla, CA) was used to conduct the statistical analysis. The data were given as mean standard deviation. To compare the means, an ANOVA was used, followed by Tukey’s post hoc test. Statistical significance was defined as \( p = .05 \).

4. Results and discussion
4.1. Experimental design
The Box–Behnken is a reliable design used in this work to prepare and optimize 2ME-INVA-APA to obtain the smallest
vesicle size. Due to its highest determination coefficient $R^2$, the two-factor interaction model was the best fit for the vesicle size data. Furthermore, the predicted and adjusted $R^2$ values were in high agreement, indicating that the model was valid. The signal-to-noise ratio was measured using adequate precision, and the computed ratio of 66.71

Figure 5. Graphical presentation of A549 cell cycle phases following treatment for 24 h using flow cytometry analysis. (A) control; (B) INVA-APA; (C) 2ME; (D) 2ME-INVA-APA; (E) graphical presentation of cell cycle phases. All data is given as the mean standard deviation of three separate studies. *$p<.05$ was considered significant when compared to the control. **$p<.05$ was considered significant when compared to INVA-APA and ***$p<.05$ was considered significant when compared to 2ME.
suggests that the chosen model can be utilized to follow the design space. Figure 2 illustrates the diagnostic plots produced to assess the goodness of 2FI interaction model fit. Figure 2(A) shows a value of the recommended lambda ($\lambda$) (0.81) in the Box–Cox plot for power transforms. The present value of 1 is contained in the 95% confidence interval (indicated by the red bounds); no specific transformation for measured size is suggested (Singh et al., 2011; Badr-Eldin

Figure 6. Analysis of apoptosis via Annexin-V-FITC staining in A549 cells. The data are stated as the mean ± SE of number of separate tests (three). (A) control; (B) INVA-APA; (C) 2ME; (D) 2ME-INVA-APA; (E) graphical presentation of cell populations. *$p < .05$ considered significantly different from the control. *$p < .05$ considered significantly different from INVA-APA and *$p < .05$ considered significantly different from 2ME.
et al., 2021). The calculated maximum to minimum size ratio of 2.31 supports the absence of transformation, where a ratio more than 10 is likely to need transformation. Within the bounds of the externally studentized residuals vs. predicted response plot, as shown in Figure 2(B), a random distribution of the measured globule size suggests that no continuous error exists. Furthermore, the residual vs. run plot, as shown in Figure 2(C), shows the distribution of random points, showing that no lurking variable may affect the measured size. The observed vs. predicted values of vesicle size, as shown in Figure 2(D), are in good agreement. This further validates the chosen design model and its potential use in forecasting the optimal formula that meets the specified requirement (Alhakamy et al., 2020).

4.1. Influence of variables on size

The prepared 2ME-INVA-APA exhibited vesicular size ranging from 173.2 to 418.3 nm. The equation of the polynomial (Equation (1)) representing the 2FI sequential model in terms of coded factors was generated.

\[
Y = 272.99 + 71.36X_1 - 38.41X_2 + 18.63X_3 - 12.25X_1X_2 + 8.97X_1X_3 - 1.63X_2X_3
\]  
(1)

Table 3 shows that the linear factors \( X_1 \) (phospholipid %), \( X_2 \) (ethanol %), and \( X_3 \) (terpene %) had a significant influence on vesicle size at \( p<.05 \). Furthermore, at the same level of significance, the interaction variables \( X_1X_2 \) and \( X_1X_3 \), which describe the interaction between phospholipid percentage and either ethanol or terpene percentage, were significant. The perturbation plot, presented in Figure 3(A), shows the independent variables effects on the vesicle size. Both variables \( X_1 \) and \( X_2 \) had a positive slope, showing a direct link between the variable and the response. The variable \( X_2 \) had a negative slope, indicating that ethanol % is inversely related to size. The positive sign of the linear components \( X_1 \) and \( X_3 \) and the negative sign of the linear term \( X_2 \) confirm the observed trend. Figure 3(B–D) shows 3D response surface plots for the tested factors’ influence on vesicle size, revealing that phospholipid percentage had the most significant effect on vesicle size. This is supported by the greatest coefficient of the term \( X_1 \) in the constructed equation.

4.2. Optimization of 2ME-INVA-APA

The optimum formulation composition was predicted using Design Expert software® (Stat-Ease Inc., Minneapolis, MN) through numerical optimization with the purpose of decreasing particle size. Table 4 shows the composition of optimized 2ME-INVA-APA. With a percent error of 2.15%, the measured vesicle size was in good agreement with the predicted value, demonstrating the design’s suitability for the optimization process.

**Figure 7.** Expression of apoptotic markers (A) Bax, (B) Bcl-2 (C) caspase-3, and (D) p53 within A549 lung cancer cells. All results are stated as the mean ± SE of three separate tests. *\( p<.05 \) was considered significant when compared to INVA-APA and $\( p<.05 \) was considered significant when compared to 2ME.
4.3. Cytotoxicity assay

MTT assay revealed that INVA-APA, 2ME, or 2ME-INVA-APA inhibited A549 cells in a dose-dependent manner. INV-APA and 2ME demonstrated inhibition of the viability of the cells with IC₅₀ values of 10.43 ± 0.39 and 5.6 ± 0.2 µg/mL, respectively (Figure 4). 2ME-INVA-APA significantly inhibited A549 cells as compared to the other two groups (p < .05) and exhibited an IC₅₀ value of 1.15 ± 0.04 µg/mL.

4.4. Cell cycle analysis

Cell cycle analysis test was conducted in order to verify whether 2ME-INVA-APA inhibited A549 cells by influencing the cell cycle phases. The A549 cells (control) demonstrated proliferative profile with around 55% at G0/G1 phase, 2% at pre-G1 phase, 15% at G2 phase, and 30% at S phase (Figure 5(A)). INV-APA and 2ME treatments significantly enhanced the number of cells in the pre-G1 and S phases of the cell cycle (p < .05) (Figure 5(B,C)). The percentage of cells at G2/M decreased to 9.29 ± 0.28% and 3.75 ± 0.16% for INVA-APA and 2ME treatments, respectively, indicating that they arrested the cell cycle at S phase. Interestingly, 2ME-INVA-APA significantly enhanced the S (47.15 ± 1.54%) and pre-G1 (38.42 ± 1.45%) phases, indicating significant arrest of A549 S phase when compared with other groups (Figure 5(D,E)).

4.5. Annexin V apoptosis assay

Annexin V and PI staining were used to assess the apoptotic rate (Figure 6(A–E)). 2ME-INVA-APA significantly increased the percentage of early/late apoptosis and necrosis (p < .05) (Figure 6) compared to 2ME.

4.6. INVA-APA modulating Bax, Bcl-2, caspase 3, and p53 protein levels

A549 cells treated with the optimized formula revealed a significant (p < .05) increase in the expression of Bax and p53 (Figure 7(A,D)). Instead, it decreased the expression of the antiapoptotic protein Bcl-2 significantly compared to plain INVA APA (Figure 7(B)). However, no significant effect was observed on caspase 3 expression in the cells treated with the optimized formula compared to plain formula (Figure 7(C)). Meanwhile, 2ME alone significantly enhanced the caspase 3 expression. The effect of the optimized formula was more prominent on Bax and Bcl2 compared to 2ME, while 2ME had more prominent influence on caspase 3 and p53 than the optimized formula.

4.7. Expression of TNF-α and NF-κB

As shown in Figure 8, treatment of A549 cell line with 2ME-INVA-APA resulted in a significant (p < .05) decrease in the expression of TNF-α (Figure 8(A)) and a significant (p < .05) reduction in the expression of activated NF-κB (Figure 8(B)) when compared with plain formula and 2ME.

4.8. Mitochondrial membrane potential study

To investigate the pro-apoptotic and anti-proliferative activity of 2ME-INVA-APA and its effect on MMP, the percentage variation with respect to MMP caused by varying treatments was analyzed. 2ME-INVA-APA resulted in significant changes in MMP as compared to control cells and cells treated with the plain formula (Figure 9(A–E)).

5. Discussion

2ME is an anti-angiogenic, anti-proliferative, and pro-apoptotic medication with a lot of promise (Fotsis et al., 1994; Becker et al., 2008). As it suppresses the proliferation of many human cancer cell lines in vitro, it might be useful in the treatment of cancer (Benedikt et al., 2010; Bu et al., 2022); however, it was found to exhibit very poor oral bioavailability and extensive metabolism (Potter, 2018). Our study was conducted to improve the therapeutic effectiveness of 2ME through its inclusion into the core of hydrophobic INVA covered with Phospholipon 90G and APA to produce 2ME-INVA-APA.

The Box–Behnken statistical design was implemented to enhance and optimize the composition. The Box–Behnken is a rotatable or nearly-rotatable three-level response surface design, commonly used in pharmaceutical research for
optimization (Khuri & Mukhopadhyay, 2010). The observed increase in vesicle size with increasing phospholipid percentage is in good agreement with previous studies for vesicular formulations. PL percent had a favorable influence on the vesicle size of ethosomes loaded with anti-psoriatic drug, according to Dubey et al. (2007). Ahmed & Badr-Eldin (2019) found that raising Phospholipon concentration increased the vesicle size of avanafil-INVA. Furthermore, an increase in size

Figure 9. The effect of INVA-APA, 2ME-raw, and 2ME-INVA-APA on MMP variation in A549 cell. Normalization of values took place with respect to untreated (control) A549 cells and expressed as variation percentage. Data denote the mean of four independent experiments ± SE. *Significantly different vs. control ($p < .05$), #significantly different vs. plain formula ($p < .05$), and $^\$p < .05$ considered significantly different from 2ME.
at higher terpene percentages has been previously reported for INVA (Dragicevic-Curic et al., 2008; Nangare & Dugam, 2020).

After optimization of the formula, the effectiveness of 2ME-INVA-APA was investigated on A549 cells and compared with 2ME and plain formula. Our results showed that 2ME-INVA-APA inhibited A549 cells and its IC_{50} value was significantly lower than IC_{50} values of 2ME and plain formula. Therefore, we can speculate that 2ME-INVA-APA could easily seep through the cell membrane and induce apoptosis despite a low dose.

Regarding cell cycle analysis, we observed that 2ME arrested the G2-M phase of A549 cells, which is in agreement with findings reported by Lee et al. (2008). Nevertheless, a further enhanced effect was seen using the optimized formula. In addition, the optimized formula resulted in a noticeable increase in the number of cells in the pre-G1 phase, which is also in agreement with previous literature (Lee et al., 2008). This increase is a characteristic sign of apoptotic potential (Mascitelli & Pezzetta, 2007; Hardie et al., 2016; Rady et al., 2017; El-Aarag et al., 2019). Notably, blank-INAVA APA decreased the cell count in the S-phase.

The apoptotic effect of the test compounds was confirmed by Annexin V staining and MMP assay. 2ME-INVA-APA significantly increased the percentage of early/late apoptosis and necrosis and resulted in significant changes in MMP. These changes in A549 profile indicate apoptosis by 2ME-INVA-APA. Wei et al. reported similar apoptotic effect for 2ME at 10 µg/mL when A549 cells were treated for 24 h. This effect has also been reported in human LC cell line H1299; however, the effect was reduced at 48 µg/mL (Wei et al., 2020).

In order to investigate the pathways that may be involved in the pro-apoptotic effect of 2ME-INVA-APA, we assessed the relative expression of Bax, Bcl-2, caspase 3, and p53. Significant upregulation of Bax and downregulation of Bcl-2 was observed in the A549 LC cells treated by 2ME-INVA-APA. This could be attributed to the increased apoptosis in the 2ME-INVA-APA treated cells. Previous studies has reported similar effect of 2ME on Bax and Bcl-2 expression (Badr-Eldin et al., 2020; Alhakamy et al., 2021). These findings substantiate 2ME-INVA-APA’s anti-neoplastic ability. P53 is a tumor suppressor gene that increases when it senses potentially oncogenic stimuli. When p53 mutates, its activity is decreased, leading to uncontrolled cell division (Li & Yuan, 2008). The optimized formula increased the expression of p53 in A549 cells, indicating that p53 plays a critical role in 2ME-INVA-mediated apoptosis at very low dose in A549 cell line.

Caspases are a broad family of cysteine proteases that are required for intrinsic apoptosis initiation and execution. A frequent downstream apoptosis effector is caspase-3 (Farnebo et al., 2010). Caspase-3 expression was upregulated in 2ME treated cells, while the effect of the optimized formula was comparable to the plain formula. This may be due to the low concentration of 2ME in the optimized formula. A previous study showed that at least 10 µM of 2ME was required to increase caspase-3 and the increase was gradual as well. This demonstrates that the intrinsic-mediated caspase-3 activation pathway is involved in 2ME mediated apoptosis (Tang et al., 2020). We reported that 2ME-INVA-APA downregulated the expression of both TNF-α and NF-κB. This effect highlights the anti-angiogenic and anti-inflammatory effects of 2ME. Moreover, the inhibition of TNF-α and upregulation of p53 by the optimized formula could make a breakthrough in cancer management (Mascitelli & Pezzetta, 2007; El-Aarag et al., 2019). TNF-α is a pleiotropic proinflammatory cytokine that regulates a variety of physiological and pathological signaling pathways including as inflammation, differentiation, proliferation, and apoptosis induction. TNF-α promotes cancer cell proliferation, migration, and adhesion in the tumor microenvironment, accelerating multistep cancer development (Liu et al., 2019).

The enhanced anti-neoplastic property of 2ME-INVA-APA can be attributed to increased release of 2ME from the INVA, as well as increased seepage through cell membrane due to the small size (Ali et al., 2013; Hua et al., 2016). Furthermore, similar potential of APA and 2ME against A549 LC cells have been reported in literature (Wang et al., 2011; Fahmy, 2018). Similarly, INVA delivery of drug-free formulation in A549 cells induces rapid necrosis.

6. Conclusions

The Box–Behnken design was implemented successfully to optimize 2ME-INVA-APA formulation with minimized size. The particle size increased with increasing both phospholipid and terpene concentrations, while it decreases at higher ethanol percentages. The optimized formulation with size of 167.8 nm showed enhanced cytotoxicity and apoptosis against A549 cells. Further, it significantly suppressed inflammatory marker activity. Therefore, the proposed formulation is a promising anti-neoplastic agent for the treatment of LC.

Disclosure statement

The authors declare no conflict of interest.

Authors contributions
Conceptualization, Z.A., M.W., M.A.S., and S.A.; methodology, A.A., H.Z., H.M., S.M., and S.A.Z.; software, N.A., S.S., and M.A.; validation, formal analysis, S.A.Z.; investigation, M.W. and M.A.; resources, M.A.; data curation, S.M. and H.M.; writing – original draft preparation, S.S., N.A., A.A., and S.A.Z.; writing – review and editing, M.A.; visualization, S.Z., M.A.E., and H.Z.; supervision, A.A.; project administration, Z.A.; funding acquisition, N.A. All authors have read and agreed to the published version of the manuscript.

Funding

This project was funded by the Deanship of Scientific Research (DSR) at King Abdulaziz University, Jeddah, under Grant No. [RG-5-166-42]. The authors, therefore, acknowledge with thanks DSR for technical and financial support.
References

Ahmed OAA, Badr-Eldin SM. (2019). Development of an optimized avanafil-loaded invasional transdermal film: ex vivo skin permeation and in vivo evaluation. Int J Pharm 570:1536.

Alfai fi MY, Shati AA, Elbehairi SEI, et al. (2020). Anti-tumor effect of PEG-coated PLGA nanoparticles of febuxostat on A549 non-small cell lung cancer cells. J Biotech 10:133.

Alhakamy NA, Ahmed OAA, Fahmy UA, et al. (2021). Development, optimization and evaluation of 2-methoxy-estradiol loaded nanocarrier for prostate cancer. Front Pharmacol 12:82337.

Alhakamy NA, Ahmed OAA, Fahmy UA, Md S. (2021). Development and in vitro evaluation of 2-methoxyestradiol loaded polymeric micelles for enhancing anticancer activities in prostate cancer. Polymers 13: 884.

Alhakamy NA, Ahmed OAA, Fahmy UA, Shadab M. (2021). Apamin-conjugated alendronate sodium nano complex for management of pancreatic cancer. Pharmaceuticals 14:729.

Alhakamy NA, Badr-Eldin SM, Ahmed OAA, et al. (2020). Piceatannol-loaded emulsomes exhibit enhanced cytostatic and apoptotic activities in colon cancer cells. Antioxidants 9:419.

Alhakamy NA, Fahmy UA, Badr-Eldin SM, et al. (2020). Optimized icarin phytosomes exhibit enhanced cytotoxicity and apoptosis-inducing activities in ovarian cancer cells. Pharmaceutica 12:346.

Ali N, Allam H, Bader T, et al. (2013). Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism. PLOS One 8:1–10.

Amirshahrokhi K, Bohlouli S. (2013). Effect of methylsulfonylmethane on paraparquet-induced acute lung and liver injury in mice. Inflammation 36:111–21.

Attalla H, Mäkelä TP, Adlercreutz H, Andersson LC. (1996). 2-Methoxyestradiol arrests cells in mitosis without depolymerizing tubulin. Biochem Biophys Res Commun 228:467–73.

Badr-Eldin SM, Alhakamy NA, Ahmed OAA, et al. (2021). Optimized semi-solid self-nanoemulsifying system based on glyceryl behenate: a potential nanoplatform for enhancing antitumor activity of raloxifene hydrochloride in MCF-7 human breast cancer cells. Int J Pharm 600:120493.

Badr-Eldin SM, Alhakamy NA, Fahmy UA, et al. (2020). Cytotoxic and pro-apoptotic effects of a sub-toxic concentration of fluvastatin on OVCAR3 ovarian cancer cells after its optimized formulation to melittin nano-conjugates. Front Pharmacol 11:642171.

Becker CM, Rohwer N, Funakoshi T, et al. (2008). 2-Methoxyestradiol inhibits hypoxia-inducible factor-1α and suppresses growth of lesions in a mouse model of endometiosis. Am J Pathol 172:534–44.

Benedikt MB, Mahlum EW, Shugren KL, et al. (2010). 2-Methoxyestradiol-mediated anti-tumor effect increases osteoprogerin expression in osteosarcoma cells. J Cell Biochem 109:950–6.

Bu S, Blaukat A, Fu X, et al. (2022). Mechanisms for 2-methoxyestradiol-induced apoptosis of prostate cancer cells. FEBS Lett 531:141–51.

Caruso G, Distefano DA, Parlassico P, et al. (2017). Receptor-mediated toxicity of human amlyn fragment aggregated by short- and long-term incubations with copper ions. Mol Cell Biochem 425:85–93.

Dragicevic-Curic N, Scheglmil D, Albrecht V, Fahr A. (2008). Temoporfin-loaded invasomes: development, characterization and in vitro skin penetration studies. J Control Release 127:59–69.

Dubey V, Mishra D, Dutta T, et al. (2007). Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J Control Release 123:148–54.

El-Aarag B, Magdy M, AlAjmi MF, et al. (2019). Melittin exerts beneficial effects on paraquat-induced lung injuries in mice by modifying oxidative stress and apoptosis. Molecules 24:1498.

Fahmy UA. (2018). Augmentation of fluvastatin cytotoxicity against prostate carcinoma PC3 cell line utilizing alpha lipoic-ellagic acid nanostructured lipid carrier formula. AAPS PharmSciTech 19: 3454–61.

Farbebo M, Bykov VJN, Wiman KG. (2010). The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun 396:85–9.

Fotsis T, Zhang Y, Pepper MS, et al. (1994). The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368:237–9.

Gu H, Han SM, Park KK. (2020). Therapeutic effects of apamin as a bee venom component for non-neoplastic disease. Toxins 12:195.

Hardie C, Jung Y, Jameson M. (2016). Effect of statin and aspirin use on toxicity and pathological complete response rate of neo-adjuvant chemoradiation for rectal cancer. Asia Pac J Clin Oncol 12:167–73.

Herbst RS, Mergensztern D, Bosshoff C. (2018). The biology and management of non-small cell lung cancer. Nature 553:446–54.

Hua P, Zhang G, Zhang Y, et al. (2016). Costunolide induces G1/S phase arrest and activates mitochondrial-mediated apoptotic pathways in SK-MES 1 human lung squamous carcinoma cells. Oncol Lett 11: 2780–6.

Khuri AI, Mukhopadhyay S. (2010). Response surface methodology. WIREs Comp Stat 2:128–49.

Lakhani NJ, Sarkar MA, Venizit J, Figg WD. (2003). 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 23:165–72.

Lee YM, Ting CM, Cheng YK, et al. (2008). Mechanisms of 2-methoxyestradiol-induced apoptosis and G2/M cell-cycle arrest of nasopharyngeal carcinoma cells. Cancer Lett 268:295–307.

Lemjabbar-Alaoui H, Hassan OUI, Yang YW, Buchanan P. (2015). Lung cancer: biology and treatment options. Biochim Biophys Acta 1856:189–210.

Li J, Yuan J. (2008). Caspases in apoptosis and beyond. Oncogene 27: 6194–206.

Liu W, Chen X, He Y, et al. (2019). TNF-α inhibits xenograft tumor formation by A549 lung cancer cells in nude mice via the HIF-1α/VASP signaling pathway. Oncol Rep 41:2418–30.

Mascitelli L, Pezzetta F. (2007). Fluvastatin and cancer: letter [1]. Int J Clin Pract 61:168.

Nangare S, Dugam S. (2020). Smart invasome synthesis, characterizations, pharmaceutical applications, and pharmacokinetic perspective: a review. Future J Pharm Sci 6:1–21.

Pillai GJ, Paul-Prasanth B, Nair SV, Menon D. (2017). Influence of surface passivation of 2-methoxyestradiol loaded PLGA nanoparticles on cellular interactions, pharmacokinetics and tumour accumulation. Colloids Surf B Biointerfaces 150:242–9.

Potter BVL. (2018). Steroid sulphatase inhibition via aryl sulphamates: pharmacodynamics, and efficacy of oral 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Life Sci 40:59–93.

Rady I, Siddiqui IA, Rady M, Mukhtar H. (2017). Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy. Cancer Lett 402:16–31.

Singh B, Bhatowa R, Tripathi C, Kapil R. (2011). Developing micro-/nano-particle drug delivery systems using “design of experiments”. Int J Pharm Invest 1:75–87.

Sweeney C, Liu G, Vianoutsos C, et al. (2005). A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res 11: 6625–33.

Tang X, Tao F, Xiang W, et al. (2020). Anticancer effects and the mechanism underlying 2-methoxyestradiol in human osteosarcoma in vitro and in vivo. Oncol Lett 20:64.

Teramoto S, Tomita T, Matsui H, et al. (1999). Hydrogen peroxide-induced apoptosis and necrosis in human lung fibroblasts: protective roles of glutathione. Jpn J Pharmacol 79:33–40.
Tevaarwerk AJ, Holen KD, Alberti DB, et al. (2009). Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies. Clin Cancer Res 15:1460–5.

Vidya K, Lakshmi PK. (2019). Cytotoxic effect of transdermal invasomal anastrozole gel on MCF-7 breast cancer cell line. J Appl Pharm Sci 9:50–8.

Wang Y, Guo R, Cao X, et al. (2011). Encapsulation of 2-methoxyestradiol within multifunctional poly(amidoamine) dendrimers for targeted cancer therapy. Biomaterials 32:3322–9.

Wei M, Li J, Qiu J, et al. (2020). Costunolide induces apoptosis and inhibits migration and invasion in H1299 lung cancer cells. Oncol Rep 43:1986–94.